[CAS NO. 312752-85-5]  YM758

Ships within Stock Price Qty Total
$0.00
$0.00
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [312752-85-5]

Catalog
HY-U00309
Brand
MCE
CAS
312752-85-5

DESCRIPTION [312752-85-5]

Overview

MDL-
Molecular Weight469.55
Molecular FormulaC26H32FN3O4
SMILESO=C([C@H]1CN(CCC1)CCNC(C2=CC=C(F)C=C2)=O)N3CC4=CC(OC)=C(OC)C=C4CC3

For research use only. We do not sell to patients.

Summary

YM758 is a “funny” I f current channel ( I f channel ) inhibitor.


IC50 & Target

I f channel [1]


In Vitro

The inhibitory effect of YM758 on [ 3 H]MPP uptake via human/rat organic cation transporters (hOCT1/rOct1) is investigated. YM758 inhibits rOct1- and hOCT1-mediated [ 3 H]MPP uptake in a concentration-dependent manner with IC 50 values of 23.8 and 40.5 μM, respectively. The IC 50 value of YM758 for [ 14 C]Metformin uptake via rOct1 may be estimated below 10 μM in the same way, whereas that is much smaller than that for [ 3 H]MPP uptake. In addition, the inhibitory effect of YM758 on [ 3 H]E 2 17βG uptake via OATP1B1 and OATP1B3 is investigated. YM758 inhibits OATP1B1-mediated [ 3 H]E 2 17βG uptake in a concentration-dependent manner with a IC 50 value of 13.0 μM. YM758 has no inhibitory effect on OATP1B3-mediated [ 3 H]E 2 17βG uptake [1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.


In Vivo

After a single intravenous administration of 0.03, 0.1, and 0.3 mg/kg to tachycardia-induced beagles, YM758 plasma concentrations rapidly decrease with t 1/2 values of 1.62, 4.93, and 1.63 h, respectively. At the corresponding doses, the CL tot values amount to 1.71, 1.69, and 1.48 L/h/kg, and Vd ss values are 3.19, 5.78, and 2.94 L/kg, respectively. Because the plasma concentration 24 h after administration is quantified only in the 0.1 mg/kg dosing group, the larger values of t 1/2 and Vd ss are obtained compared with those in other dosing groups. The PK profile of YM758 in tachycardia-induced dogs appeares to be linear within the dose range of 0.03 to 0.3 mg/kg. The CL tot of YM758 in the blood basis (CL b,dog ) is estimated to be 1.47 to 1.69 L/h/kg [2] . The radioactivity in the rat eyeballs after dosing 14 C-YM758 is extracted with a mixture of 2 mol/L hydrochloric acid and Methanol (5:95, v/v); the radioactivity recovery is 97.1% at 4 h and 67.1% at 24 h. The HPLC recovery of radioactivity from the extracted samples is 90.6 and 100.6% at 4 and 24 h, respectively. In the eyeball at 4 h after administration, YM758 (the unchanged drug) is the main compound detected (66.7%), and the metabolites YM-252124 (14.5%), YM-394111 (2.4%), and YM-234903 (1.8%) are also observed [3] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.


Appearance

Solid


Shipping

Room temperature in continental US; may vary elsewhere.


Storage

Powder -20°C 3 years
In solvent -80°C 6 months
-20°C 1 month

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL ( 212.97 mM ; ultrasonic and warming and heat to 60°C)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.1297 mL 10.6485 mL 21.2970 mL
5 mM 0.4259 mL 2.1297 mL 4.2594 mL
10 mM 0.2130 mL 1.0648 mL 2.1297 mL
* Please refer to the solubility information to select the appropriate solvent.